Drugs / RIFAQUIZINONE
RIFAQUIZINONE
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06394518 | Jul 2022 → Feb 2023 | periprosthetic joint infection | TenNor Therapeutics Limited | Completed | No outcome recorded |
| Phase 1 | NCT05074134 | Oct → Nov 2021 | — | TenNor Therapeutics Limited | Completed | No outcome recorded |
| Phase 1 | NCT04294862 | Mar → Dec 2021 | periprosthetic joint infection | TenNor Therapeutics Limited | Completed | No outcome recorded |
| Phase 1 | NCT06337604 | Oct → Nov 2017 | Helicobacter pylori infectious disease | TenNor Therapeutics Limited | Completed | No outcome recorded |
| Phase 1 | NCT06190340 | Nov 2016 → Sep 2017 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06178718 | Jun → Aug 2016 | — | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06889701 | Apr 2025 → Aug 2026 overdue | periprosthetic joint infection | TenNor Therapeutics Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06135675 | Aug 2020 → Jun 2021 | — | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07858916 | Oct 2026 → Sep 2027 expected | periprosthetic joint infection | TenNor Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03964493 | Apr 2019 → Sep 2020 | gram-positive bacterial infections, skin disease caused by bacterial infection | TenNor Therapeutics Limited | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RIFAQUIZINONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594404 ↗ |
| Known as | [14C]-TNP-2092 | “Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).” NCT05074134 ↗ |
| Known as | Cbr-2092 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594404 ↗ |
| Known as | Rifaquizinona | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594404 ↗ |
| Known as | rifaquizinone for injection | “rifaquizinone for injection” NCT06889701 ↗ |
| Known as | TNP-2092 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07858916 ↗ |
| Modality | Small molecule | — CHEMBL4594404 ↗ |
| Route | Intravenous | “TNP-2092 300 mg intravenous every 12 hours” NCT03964493 ↗ |